Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
November 21 2019 - 4:02PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated
pharmaceutical company pioneering time-dependent medicines for
central nervous system disorders, today announced that Neil F.
McFarlane, the Company’s Chief Executive Officer, is scheduled to
present at the following investor conferences:
- Evercore ISI 2nd Annual HealthCONx
Conference on Tuesday, December 3 at 9:50 a.m. ET (6:50 a.m.
PT)
- Piper Jaffray 31st Annual Healthcare Conference on Wednesday,
December 4 at 4:00 p.m. ET (1:00 p.m. PT)
The presentation will be webcast live from the
investor relations section of the Adamas website at
http://ir.adamaspharma.com/events-presentations. An archived
version of the webcast will be available via replay for 30 days
following the presentations.
About Adamas Pharmaceuticals,
Inc.Adamas’ goal is to create and commercialize a new
generation of medicines intended to lessen the burden of chronic
neurologic diseases on patients, caregivers and society using its
deep understanding of time-dependent biology. The Company is
focused on the commercialization of GOCOVRI® (amantadine) extended
release capsules, the first and only FDA-approved medicine for the
treatment of dyskinesia in patients with Parkinson’s disease
receiving levodopa-based therapy, with or without concomitant
dopaminergic medications. The Company also continues to deliver
differentiated investigational programs, including ADS-5102 in
development for the treatment of walking impairment in patients
with multiple sclerosis. For more information about Adamas and its
unique approach to developing medicines based on time-dependent
biology, please visit www.adamaspharma.com.
Contact:
Investors: Peter VozzoManaging Director,
Westwicke443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President of
Corporate Communications510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024